Publications by authors named "Veronica Guglielmana"
Anaplastic lymphoma kinase positive (ALK+) anaplastic large cell lymphoma (ALCL) typically affects young individuals and, despite high responsiveness to cytotoxic drugs, relapses occur in over 50% of patients. Crizotinib has improved outcomes, but its management in patients desiring parenthood remains an issue. This study presents the first description of four successful pregnancies during crizotinib treatment for ALK+ALCL: a female patient achieving two pregnancies through assisted reproductive technologies (ART), temporarily discontinuing crizotinib and maintaining a complete remission (CR), and a male patient conceiving naturally while on continuous therapy.
View Article and Find Full Text PDFMutations in the oncogene are recurrently linked to chronic lymphocytic leukemia (CLL), found in approximately 10% of CLL cases at diagnosis. Although these mutations are associated with clinical outcomes, their significance in the context of treatment with anti-CD20 monoclonal antibodies, Bruton's tyrosine kinase inhibitors, and BCL2 inhibitors remains controversial. Consequently, testing for mutations is not recommended outside of a clinical setting.
View Article and Find Full Text PDFArticle Synopsis
- Ruxolitinib (RUX) is a treatment for myelofibrosis, mainly studied in high-risk patients, but is often given to intermediate-1 patients with limited data on its effects.
- In a study of 1,055 myelofibrosis patients, over half were classified as intermediate-1 risk, with notable symptoms and some having high-molecular-risk mutations.
- The study found that after 6 months of RUX treatment, a significant proportion of patients experienced improvements in spleen size and symptoms, with certain factors like the absence of high-molecular-risk mutations being linked to better treatment responses.
Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO study.
Am J Hematol
November 2023
Article Synopsis
- The study investigates the risk of disease progression to accelerated/blast phase (AP/BP) in patients with chronic myeloid leukemia (CML) after stopping treatment, addressing concerns raised by recent case reports.
- A total of 870 patients were analyzed, with 505 in the treatment discontinuation (TD) cohort and 365 in a reference cohort, and the primary focus was on the time-adjusted rate (TAR) of progression and molecular relapse.
- Findings showed that progression to AP/BP was extremely rare in the TD cohort, with no significant difference in TAR between the cohorts, suggesting that the risk of disease progression after stopping treatment should not be a major concern.
Introduction: COVID-19 pandemic had a considerable impact among haematological patients. On the other hand, the effect of this disease on patients (pts) affected by Chronic Myeloid Leukemia (CML) is not clearly defined.
Objectives: The primary objective of this study was to evaluate mortality-hospitalization rates and possible protective factors for hospitalization in CML pts affected by COVID.